Sam Chun Dang Pharm. Co., Ltd
000250
Rang in aandelen
#4333
Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and... Sam Chun Dang Pharm Co., Ltd. is a pharmaceutical company that develops and produces a wide variety of medications. Its product range features antibiotics, treatments for cardiovascular and respiratory conditions, drugs for the digestive system and ophthalmic use, as well as anti-inflammatory agents. The company was founded on December 29, 1943, and its main operations are based in Hwaseong-si, South Korea.
Aandeelprijs
$152.58
Marktkapitalisatie
$3.57B
Verandering (1 dag)
3.84%
Verandering (1 jaar)
6.02%
Land
KR
Handel Sam Chun Dang Pharm. Co., Ltd (000250)
Categorie
Healthcare
EPS voor Sam Chun Dang Pharm. Co., Ltd (000250)
EPS per June 2026 TTM: $0.57
Volgens de laatste financiële rapporten en de aandelenkoers van Sam Chun Dang Pharm. Co., Ltd is de huidige EPS van het bedrijf (TTM) $0.57. Eind 2024 had het bedrijf een EPS van $-0.32, een daling ten opzichte van de EPS van 2023 die $-0.36 bedroeg.
EPS-geschiedenis van Sam Chun Dang Pharm. Co., Ltd van 2004 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $0.57 | 259.19% |
| 2025 | $0.16 | -148.54% |
| 2024 | $-0.32 | -9.81% |
| 2023 | $-0.36 | -270.66% |
| 2022 | $0.21 | -133.22% |
| 2021 | $-0.63 | 1,435.28% |
| 2020 | $-0.04 | -109.72% |
| 2019 | $0.42 | 15.11% |
| 2018 | $0.37 | -33.10% |
| 2017 | $0.55 | 56.72% |
| 2016 | $0.35 | -27.77% |
| 2015 | $0.49 | -7.21% |
| 2014 | $0.52 | 22.56% |
| 2013 | $0.43 | 558.18% |
| 2012 | $0.06 | -74.37% |
| 2011 | $0.25 | 13.41% |
| 2010 | $0.22 | -4.91% |
| 2009 | $0.23 | -4.56% |
| 2008 | $0.25 | -23.37% |
| 2007 | $0.32 | 142.07% |
| 2006 | $0.13 | -58.91% |
| 2005 | $0.32 | -8.44% |
| 2004 | $0.35 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $2.41 | 319.35% |
US
|
|
| $0.40 | -30.07% |
SE
|
|
| $6.96 | 1,111.54% |
FR
|
|
| $2.73 | 374.84% |
IT
|
|
| $0.52 | -9.52% |
US
|
